September 29, 2022
Loading...
You are here:  Home  >  Current Article

Amgen escapes lawsuit

IN THIS ARTICLE

Ariad Pharmaceuticals lost its appeals court bid to demand royalties from Amgen over the arthritis drug Enbrel, Bloomberg news reported. Enbrel is Thousand Oaks-based Amgen’s top-selling drug with sales of $758 million in the first quarter.

The U.S. Court of Appeals for the Federal Circuit in Washington said a lower-court judge was correct in his interpretation of certain aspects of the Ariad patent and in finding that Amgen doesn’t infringe the patent.

Are you a subscriber? If not, sign up today for a four-week FREE trial or subscribe and receive the 2009 Book of Lists free with your purchase.